Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | IDH1 | O75874 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045983 | 1.00 | MEN1 (0.57) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL21045992 | 0.87 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21045993 | 0.87 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21045869 | 0.81 | MEN1 (0.54) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL21045871 | 0.81 | MEN1 (0.54) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL21045870 | 0.81 | MEN1 (0.54) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL24121640 | 0.80 | MEN1 (0.68) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL24121635 | 0.78 | MEN1 (0.57) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL21045897 | 0.75 | MEN1 (0.61) | MEN1KMT2AIDH1SMN1; SMN2LMNA | |
| SCHEMBL21045899 | 0.75 | MEN1 (0.61) | MEN1KMT2AIDH1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885IDH1 690/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885IDH1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.